Human studies have evaluated tirzepatide across type 2 diabetes, obesity and weight management, cardiovascular and cardiometabolic outcomes, body composition, weight maintenance, comparative effectiveness, and safety. The evidence includes randomized controlled trials from the SURPASS programme for type 2 diabetes and the SURMOUNT programme for obesity, alongside systematic reviews, meta-analyses, and pre-specified cardiovascular outcome analyses, each linked directly to its PubMed or DOI source. The strongest body of evidence covers glycaemic and weight-related outcomes, with a growing evidence base in cardiovascular, cardiometabolic, and weight-maintenance research.
Findings vary by study population, dose, comparator, treatment duration, and clinical endpoint. Some sections in this library are supported by a smaller number of records than the primary diabetes and weight-management evidence. The collection does not establish identical outcomes for every patient, universal superiority over all other treatments, or outcomes after treatment discontinuation in all populations. Readers should review each study's design, population, findings, and limitations through the linked original source.
